Literature DB >> 33389129

A missense allele of PEX5 is responsible for the defective import of PTS2 cargo proteins into peroxisomes.

Muhammad Ali1, Shahid Y Khan1, Tony A Rodrigues2,3,4, Tânia Francisco2,3,4, Xiaodong Jiao5, Hang Qi5, Firoz Kabir1,6, Bushra Irum1,6, Bushra Rauf1,6, Asma A Khan6, Azra Mehmood6, Muhammad Asif Naeem6, Muhammad Zaman Assir7, Muhammad Hassaan Ali7, Mohsin Shahzad8,9, Khaled K Abu-Amero10, Shehla Javed Akram11, Javed Akram12, Sheikh Riazuddin7,8,9, Saima Riazuddin13, Michael L Robinson14, Myriam Baes15, Jorge E Azevedo2,3,4, J Fielding Hejtmancik5, S Amer Riazuddin16.   

Abstract

Peroxisomes, single-membrane intracellular organelles, play an important role in various metabolic pathways. The translocation of proteins from the cytosol to peroxisomes depends on peroxisome import receptor proteins and defects in peroxisome transport result in a wide spectrum of peroxisomal disorders. Here, we report a large consanguineous family with autosomal recessive congenital cataracts and developmental defects. Genome-wide linkage analysis localized the critical interval to chromosome 12p with a maximum two-point LOD score of 4.2 (θ = 0). Next-generation exome sequencing identified a novel homozygous missense variant (c.653 T > C; p.F218S) in peroxisomal biogenesis factor 5 (PEX5), a peroxisome import receptor protein. This missense mutation was confirmed by bidirectional Sanger sequencing. It segregated with the disease phenotype in the family and was absent in ethnically matched control chromosomes. The lens-specific knockout mice of Pex5 recapitulated the cataractous phenotype. In vitro import assays revealed a normal capacity of the mutant PEX5 to enter the peroxisomal Docking/Translocation Module (DTM) in the presence of peroxisome targeting signal 1 (PTS1) cargo protein, be monoubiquitinated and exported back into the cytosol. Importantly, the mutant PEX5 protein was unable to form a stable trimeric complex with peroxisomal biogenesis factor 7 (PEX7) and a peroxisome targeting signal 2 (PTS2) cargo protein and, therefore, failed to promote the import of PTS2 cargo proteins into peroxisomes. In conclusion, we report a novel missense mutation in PEX5 responsible for the defective import of PTS2 cargo proteins into peroxisomes resulting in congenital cataracts and developmental defects.

Entities:  

Year:  2021        PMID: 33389129     DOI: 10.1007/s00439-020-02238-z

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  59 in total

1.  Generation of Pex5-loxP mice allowing the conditional elimination of peroxisomes.

Authors:  M Baes; M Dewerchin; A Janssen; D Collen; P Carmeliet
Journal:  Genesis       Date:  2002-02       Impact factor: 2.487

Review 2.  Functions of plasmalogen lipids in health and disease.

Authors:  Nancy E Braverman; Ann B Moser
Journal:  Biochim Biophys Acta       Date:  2012-05-22

Review 3.  Peroxisome targeting signal 1: is it really a simple tripeptide?

Authors:  Cécile Brocard; Andreas Hartig
Journal:  Biochim Biophys Acta       Date:  2006-08-24

4.  Mapping the cargo protein membrane translocation step into the PEX5 cycling pathway.

Authors:  Inês S Alencastre; Tony A Rodrigues; Cláudia P Grou; Marc Fransen; Clara Sá-Miranda; Jorge E Azevedo
Journal:  J Biol Chem       Date:  2009-07-23       Impact factor: 5.157

5.  A peroxisomal disorder of severe intellectual disability, epilepsy, and cataracts due to fatty acyl-CoA reductase 1 deficiency.

Authors:  Rebecca Buchert; Hasan Tawamie; Christopher Smith; Steffen Uebe; A Micheil Innes; Bassam Al Hallak; Arif B Ekici; Heinrich Sticht; Bernd Schwarze; Ryan E Lamont; Jillian S Parboosingh; Francois P Bernier; Rami Abou Jamra
Journal:  Am J Hum Genet       Date:  2014-10-30       Impact factor: 11.025

6.  Human PEX7 encodes the peroxisomal PTS2 receptor and is responsible for rhizomelic chondrodysplasia punctata.

Authors:  N Braverman; G Steel; C Obie; A Moser; H Moser; S J Gould; D Valle
Journal:  Nat Genet       Date:  1997-04       Impact factor: 38.330

7.  Mutation analysis of PEX7 in 60 probands with rhizomelic chondrodysplasia punctata and functional correlations of genotype with phenotype.

Authors:  Nancy Braverman; Li Chen; Paul Lin; Cassandra Obie; Gary Steel; Pamela Douglas; Pranesh K Chakraborty; Joe T R Clarke; Avihu Boneh; Ann Moser; Hugo Moser; David Valle
Journal:  Hum Mutat       Date:  2002-10       Impact factor: 4.878

8.  A novel type of rhizomelic chondrodysplasia punctata, RCDP5, is caused by loss of the PEX5 long isoform.

Authors:  Tuva Barøy; Janet Koster; Petter Strømme; Merel S Ebberink; Doriana Misceo; Sacha Ferdinandusse; Asbjørn Holmgren; Timothy Hughes; Else Merckoll; Jostein Westvik; Berit Woldseth; John Walter; Nick Wood; Bjørn Tvedt; Kristine Stadskleiv; Ronald J A Wanders; Hans R Waterham; Eirik Frengen
Journal:  Hum Mol Genet       Date:  2015-07-28       Impact factor: 6.150

Review 9.  The biological significance of plasmalogens in defense against oxidative damage.

Authors:  T Brosche; D Platt
Journal:  Exp Gerontol       Date:  1998-08       Impact factor: 4.032

10.  An isoform of pex5p, the human PTS1 receptor, is required for the import of PTS2 proteins into peroxisomes.

Authors:  N Braverman; G Dodt; S J Gould; D Valle
Journal:  Hum Mol Genet       Date:  1998-08       Impact factor: 6.150

View more
  2 in total

1.  A genomic deletion encompassing CRYBB2-CRYBB2P1 is responsible for autosomal recessive congenital cataracts.

Authors:  Bushra Irum; Firoz Kabir; Nadav Shoshany; Shahid Y Khan; Bushra Rauf; Muhammad Asif Naeem; Tanveer A Qaiser; Sheikh Riazuddin; J Fielding Hejtmancik; S Amer Riazuddin
Journal:  Hum Genome Var       Date:  2022-09-08

2.  Next-generation whole exome sequencing to delineate the genetic basis of primary congenital glaucoma.

Authors:  Bushra Rauf; Shahid Y Khan; Xiaodong Jiao; Bushra Irum; Ramla Ashfaq; Mubashra Zehra; Asma A Khan; Muhammad Asif Naeem; Mohsin Shahzad; Sheikh Riazuddin; J Fielding Hejtmancik; S Amer Riazuddin
Journal:  Sci Rep       Date:  2022-10-14       Impact factor: 4.996

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.